Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). Methods: Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose. Results: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (<38 years) vs. older participants (<38 vs. 47–56 p = 0.002; <38 vs. >56 p = 0.001). Higher antibody levels were detected in underweight vs. pre-obesity group (p = 0.026) and in normal-weight vs. pre-obesity group (p = 0.007). This association was confirmed after adjusting for age (p = 0.0001) and gender (p = 0.00001). Conclusions: Our study demonstrates that a single dose of BNT162b2 activates the immune response, and being young and normal-weight correlate positively with this response. Larger specifically designed clinical trials are needed to validate these results.

Early onset of SARS-CoV-2 antibodies after first dose of BNT162b2: correlation with age, gender and BMI / Pellini, R.; Venuti, A.; Pimpinelli, F.; Abril, E.; Blandino, G.; Campo, F.; Conti, L.; De Virgilio, A.; De Marco, F.; Di Domenico, E. G.; Di Bella, O.; Di Martino, S.; Ensoli, F.; Giannarelli, D.; Mandoj, C.; Manciocco, V.; Marchesi, P.; Mazzola, F.; Moretto, S.; Petruzzi, G.; Petrone, F.; Pichi, B.; Pontone, M.; Zocchi, J.; Vidiri, A.; Vujovic, B.; Piaggio, G.; Morrone, A.; Ciliberto, G.. - In: VACCINES. - ISSN 2076-393X. - 9:7(2021). [10.3390/vaccines9070685]

Early onset of SARS-CoV-2 antibodies after first dose of BNT162b2: correlation with age, gender and BMI

Campo F.;De Virgilio A.;Di Domenico E. G.;Di Bella O.;Ensoli F.;Manciocco V.;Pontone M.;
2021

Abstract

Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). Methods: Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose. Results: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (<38 years) vs. older participants (<38 vs. 47–56 p = 0.002; <38 vs. >56 p = 0.001). Higher antibody levels were detected in underweight vs. pre-obesity group (p = 0.026) and in normal-weight vs. pre-obesity group (p = 0.007). This association was confirmed after adjusting for age (p = 0.0001) and gender (p = 0.00001). Conclusions: Our study demonstrates that a single dose of BNT162b2 activates the immune response, and being young and normal-weight correlate positively with this response. Larger specifically designed clinical trials are needed to validate these results.
2021
antibodies; COVID-19; obesity; SARS-CoV-2; serum titer; vaccine
01 Pubblicazione su rivista::01a Articolo in rivista
Early onset of SARS-CoV-2 antibodies after first dose of BNT162b2: correlation with age, gender and BMI / Pellini, R.; Venuti, A.; Pimpinelli, F.; Abril, E.; Blandino, G.; Campo, F.; Conti, L.; De Virgilio, A.; De Marco, F.; Di Domenico, E. G.; Di Bella, O.; Di Martino, S.; Ensoli, F.; Giannarelli, D.; Mandoj, C.; Manciocco, V.; Marchesi, P.; Mazzola, F.; Moretto, S.; Petruzzi, G.; Petrone, F.; Pichi, B.; Pontone, M.; Zocchi, J.; Vidiri, A.; Vujovic, B.; Piaggio, G.; Morrone, A.; Ciliberto, G.. - In: VACCINES. - ISSN 2076-393X. - 9:7(2021). [10.3390/vaccines9070685]
File allegati a questo prodotto
File Dimensione Formato  
Pellini_Early onset_2021.pdf

accesso aperto

Note: https://www.mdpi.com/2076-393X/9/7/685
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 264.99 kB
Formato Adobe PDF
264.99 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1637067
Citazioni
  • ???jsp.display-item.citation.pmc??? 37
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 34
social impact